CHILDHOOD OSTEOPOROSIS AND PRESENTATION OF TWO CASES WITH OSTEOGENESIS IMPERFECTA TYPE V

被引:2
|
作者
Bratanic, Nina [1 ]
Dzodan, Bojana [1 ]
Trebusak Podkrajsek, Katarina [2 ,4 ]
Bertok, Sara [1 ]
Ostanek, Barbara [3 ]
Marc, Janja [3 ]
Battelino, Tadej [1 ,4 ]
Avbelj Stefanija, Magdalena [1 ]
机构
[1] Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab Dis, Ljubljana 1000, Slovenia
[2] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Unit Special Lab Diagnost, Ljubljana 1000, Slovenia
[3] Univ Ljubljana, Fac Farmacy, Ljubljana 1000, Slovenia
[4] Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia
来源
ZDRAVSTVENO VARSTVO | 2015年 / 54卷 / 02期
关键词
bone mineral density; hypertrophic callus; IFITM5; gene; bisphosphonates; HYPERPLASTIC CALLUS FORMATION; BISPHOSPHONATE THERAPY; PHENOTYPIC VARIABILITY; FOLLOW-UP; MUTATION; CHILDREN; FRACTURES; POLYMORPHISM; ADOLESCENTS; PAMIDRONATE;
D O I
10.1515/sjph-2015-0018
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction. Osteogenesis imperfecta (OI) is etiologically heterogeneous disorder characterized by childhood osteoporosis. A subtype OI type V is caused by the same c.-14C>T mutation in the IFITM5 gene. Nevertheless, there is a marked interindividual phenotypic variability in clinical presentation; however, response to bisphosphonates is reported to be good. Methods. Two individuals with OI type V had multiple recurrent fractures with hypertrophic calluses, scoliosis and ossifications of the forearm interosseous membranes. Sequencing of IFITM5, genotyping of variants rs2297480 in farnesyl diphosphate synthase gene (FDPS), and rs3840452 in geranylgeranyl diphosphate synthase 1 gene (GGPS1), both involved in bisphosphonate metabolism, was performed. Results. In patient 1 BMD reached normal values during bisphosphonate treatment and remained normal four years after the treatment discontinuation. In patient 2 no increase in BMD after five years of bisphosphonate treatment was observed and callus formation continued. The c.-14C>T IFITM5 mutation in heterozygous state was detected in both individuals. Additionally, both patients carried FDPS variant rs2297480 in homozygous state, and were heterozygous for GGPS 1 variant rs3840452. Conclusions. The paper presents a short overview of childhood osteoporosis with a special emphasis on OI type V by presenting two cases. Both OI type V patients had identical disease-causing mutation, but marked interindividual phenotypic variability. The striking failure in response to bisphosphonate treatment in one of the patients could not be explained by the variants in genes involved in bisphosphonate metabolism.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [1] Radiological Features of Osteogenesis Imperfecta Type V: a Report of Two Cases
    Hui, P. K. T.
    Tung, J. Y. L.
    To, M. K. T.
    Chow, W.
    Lam, W. W. M.
    Chau, M. T.
    HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (01): : 36 - 40
  • [2] Type V osteogenesis imperfecta undergoing surgical correction for scoliosis
    Jones, Morgan
    Breakwell, Lee
    Cole, Ashley
    Arundel, Paul
    Bishop, Nick
    EUROPEAN SPINE JOURNAL, 2018, 27 (09) : 2079 - 2084
  • [3] Osteogenesis imperfecta type V
    Hui, Peter Kei Tat
    Tung, Joanna Y. L.
    Lam, Wendy W. M.
    Chau, M. T.
    SKELETAL RADIOLOGY, 2011, 40 (12) : 1633 - 1633
  • [4] Oro-dental and cranio-facial characteristics of osteogenesis imperfecta type V
    Retrouvey, Jean-Marc
    Taqi, Doaa
    Tamimi, Faleh
    Dagdeviren, Didem
    Glorieux, Francis H.
    Lee, Brendan
    Hazboun, Renna
    Krakow, Deborah
    Sutton, V. Reid
    Bober, Michael
    Esposito, Paul
    Eyre, David R.
    Gomez, Danielle
    Harris, Gerald
    Hart, Tracy
    Jain, Mahim
    Krisher, Jeffrey
    Nagamani, Sandesh C. S.
    Orwoll, Eric S.
    Raggio, Cathleen L.
    Rush, Eric
    Smith, Peter
    Tosi, Laura
    Rauch, Frank
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2019, 62 (12)
  • [5] Expanding the Clinical Spectrum of Osteogenesis Imperfecta Type V: 13 Additional Patients and Review
    Cao, Yang-Jia
    Wei, Zhe
    Zhang, Hao
    Zhang, Zhen-Lin
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [6] Intravenous Pamidronate in Osteogenesis Imperfecta Type VII
    Cheung, Moira S.
    Glorieux, Francis H.
    Rauch, Frank
    CALCIFIED TISSUE INTERNATIONAL, 2009, 84 (03) : 203 - 209
  • [7] Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation
    Blouin, Stephane
    Fratzl-Zelman, Nadja
    Glorieux, Francis H.
    Roschger, Paul
    Klaushofer, Klaus
    Marini, Joan C.
    Rauch, Frank
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (09) : 1884 - 1892
  • [8] Osteogenesis Imperfecta Type V: Clinical and Radiographic Manifestations in Mutation Confirmed Patients
    Kim, Ok-Hwa
    Jin, Dong-Kyu
    Kosaki, Keisuke
    Kim, Jung-Wook
    Cho, Sung Yoon
    Yoo, Won Joon
    Choi, In Ho
    Nishimura, Gen
    Ikegawa, Shiro
    Chos, Tae-Joon
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161 (08) : 1972 - 1979
  • [9] Craniocervical abnormalities in osteogenesis imperfecta type V
    Ludwig, K.
    Seiltgens, C.
    Ibba, A.
    Saran, N.
    Ouellet, J. A.
    Glorieux, F.
    Rauch, F.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (01) : 177 - 183
  • [10] Specific Characteristic of Hyperplastic Callus in a Larger Cohort of Osteogenesis Imperfecta Type V
    Zheng, Wen-bin
    Hu, Jing
    Zhang, Jia
    Yang, Zheng
    Wang, Ou
    Jiang, Yan
    Xia, Wei-bo
    Xing, Xiao-ping
    Yu, Wei
    Li, Mei
    CALCIFIED TISSUE INTERNATIONAL, 2022, 110 (04) : 451 - 463